Mounjaro is generally considered for adults with a BMI that falls into the overweight or obese range, particularly when weight-related health conditions such as insulin resistance, high blood pressure, or elevated cholesterol are also present
Intravenous administration of 50 mg lisdexamfetamine dimesylate to individuals with a history of drug abuse produced positive subjective responses on scales measuring "Drug Liking", "Euphoria", "Amphetamine Effects", and "Benzedrine Effects" that were greater than placebo but less than those produced by an equivalent dose (20 mg) of intravenous d-amphetamine
Several theories exist: The additive effects theory suggests that GIP and GLP-1 work through partially independent pathways
Zepbound (tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
Why the Scale May Not Move Right Away One of the biggest frustrations with semaglutide is feeling less hungry but not seeing immediate weight loss
Kristina has a strong focus on weight management, utilizing evidence-based strategies to support sustainable fat loss, improve metabolic health, and enhance overall well-being
